Our Intellectual Property strategy relies on the evaluation of the valorisation potential at short- and mid-term as well as on the scientific benefit/valorisation balance. Two main strategies are followed. Either the laboratory’s PI is patented for securing preliminary results and being able to gather a team aimed to perform a pre-industrial development. Or, the results are obtained in the frame of an Industrial collaboration and are advanced by our partner.
Hence three companies were directly built-up from the research performed by the LFCS laboratory.
Novalix
www.novalix-pharma.com/NovAliX is a private company combining structural biology, medicinal chemistry and an in-house developed screening technology to conduct integrated drug discovery programs. NovAliX provides target-driven solutions for drug discovery offering access to diverse and relevant approaches such as natural product-based drug discovery and fragment-based drug design (FBDD).
The fragment selection process (FAMASS) is powered by an innovative mass spectrometry screening technology delivering high-content information on compound-protein interactions (binding evidence, stoichiometry, reversibility, specificity, binding affinity…).
This biophysical method is also advantageously used for library hit validation and hit or lead analog ranking. In addition, through its integrated platform in chemistry and biology,
NovAliX provides various single services in organic synthesis and protein crystallography. As of today, NovAliX operates in Strasbourg with 60 scientists in state-of-the-art facilities (1600 m2) equipped to carry out multidisciplinary research.
This biophysical method is also advantageously used for library hit validation and hit or lead analog ranking. In addition, through its integrated platform in chemistry and biology,
NovAliX provides various single services in organic synthesis and protein crystallography. As of today, NovAliX operates in Strasbourg with 60 scientists in state-of-the-art facilities (1600 m2) equipped to carry out multidisciplinary research.
Phytodia SAS
www.phytodia.comPhytoDia identifies and characterize high value active compounds derived from plant for the nutraceutical management of metabolic diseases. The company offers the capacity to demonstrate the full potential of plant extracts, a process that addresses the needs of regulatory authorities and consumers.PhytoDia operates a performing service plateforme which encompasses pharmacognosy expertise, phytochemistry, analytical tools, advanced molecular screenings, cellular assays and in vivo models. This broad technology base is designed for a fast moving process leading to the characterization and purification of plant extracts and enabling the pharmacological validation of active compounds.
eNovalys
www.enovalys.comeNovalys has developed a breakthrough information technologies dedicated to chemistry and an integrated environment which will connect the chemist to their different partners (chemical suppliers, editors, equipment vendors...). This novel tool providing chemists with ready to use reaction conditions will enable pharmaceutical companies to increase they chemistry throughput, by up to 70%